Your vote is IMPORTANT!
Please vote your proxy online now or by phone by dialing 866-206-4393.
August 18, 2021
10:00 AM ET
To Register for the Meeting
Deadline to Register*
August 17, 2021
5:00 PM ET
*Note: You must register by the deadline to be eligible to participate in the meeting.
NeuBase Therapeutics, Inc., is developing the next generation of gene silencing therapies with its flexible, highly specific synthetic antisense oligonucleotides.
The proprietary NeuBase peptide-nucleic acid (PNA) antisense oligonucleotide (PATrOL™) platform allows for the rapid development of targeted drugs, increasing the treatment opportunities for the hundreds of millions of people affected by rare genetic diseases, including those that can only be treated through accessing of secondary RNA structures. Using PATrOL technology, NeuBase aims to first tackle rare, genetic neurological disorders.